Targeting	O
PRMT5	O
through	O
PROTAC	O
for	O
the	O
treatment	O
of	O
triple	O
negative	O
breast	O
cancer	O
.	O

BACKGROUND	O
:	O
Triple	O
negative	O
breast	O
cancer	O
TNBC	O
is	O
currently	O
the	O
most	O
aggressive	O
subtype	O
of	O
breast	O
cancer	O
characterized	O
by	O
high	O
heterogeneity	O
and	O
strong	O
invasiveness	O
and	O
currently	O
lacks	O
effective	O
therapies	O
.	O

PRMT5	O
a	O
type	O
II	O
protein	O
arginine	O
methyltransferase	O
is	O
upregulated	O
in	O
numerous	O
cancers	O
including	O
TNBC	O
and	O
plays	O
a	O
critical	O
role	O
marked	O
it	O
as	O
an	O
attractive	O
therapeutic	O
target	O
.	O

PROTAC	O
Proteolysis	O
Targeting	O
Chimeras	O
is	O
an	O
innovative	O
drug	O
development	O
technology	O
that	O
utilizes	O
the	O
ubiquitin	O
proteasome	O
system	O
UPS	O
to	O
degrade	O
target	O
proteins	O
which	O
is	O
characterized	O
by	O
higher	O
activity	O
enhanced	O
safety	O
lower	O
resistance	O
and	O
reduced	O
toxicity	O
offering	O
significant	O
value	O
for	O
clinical	O
translation	O
.	O

METHODS	O
:	O
This	O
study	O
utilizes	O
the	O
PROTAC	O
technology	O
to	O
develop	O
potential	O
degraders	O
targeting	O
PRMT5	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

RESULTS	O
:	O
Through	O
the	O
design	O
synthesis	O
and	O
screening	O
of	O
a	O
series	O
of	O
targeted	O
compounds	O
we	O
identified	O
YZ	O
836P	O
as	O
an	O
effective	O
compound	O
that	O
exerted	O
cytotoxic	O
effects	O
and	O
reduced	O
the	O
protein	O
levels	O
of	O
PRMT5	O
and	O
its	O
key	O
downstream	O
target	O
protein	O
KLF5	O
in	O
TNBC	O
after	O
48	O
h	O
.	O

Its	O
efficacy	O
was	O
significantly	O
superior	O
to	O
the	O
PRMT5	O
PROTAC	O
degraders	O
that	O
had	O
been	O
reported	O
.	O

YZ	O
836P	O
induced	O
G1	O
phase	O
cell	O
cycle	O
arrest	O
and	O
significantly	O
induced	O
apoptosis	O
in	O
TNBC	O
cells	O
.	O

Additionally	O
we	O
demonstrated	O
that	O
YZ	O
836P	O
promoted	O
the	O
ubiquitination	O
and	O
degradation	O
of	O
PRMT5	O
in	O
a	O
cereblon	O
CRBN	O
dependent	O
manner	O
.	O

Notably	O
YZ	O
836P	O
exhibited	O
pronounced	O
efficacy	O
in	O
inhibiting	O
the	O
growth	O
of	O
TNBC	O
patient	O
derived	O
organoids	O
and	O
xenografts	O
in	O
nude	O
mice	O
.	O

CONCLUSIONS	O
:	O
These	O
findings	O
position	O
YZ	O
836P	O
as	O
a	O
promising	O
candidate	O
for	O
advancing	O
treatment	O
modalities	O
for	O
TNBC	O
.	O

TRIAL	O
REGISTRATION	O
:	O
Ethics	O
Committee	O
of	O
Yunnan	O
Cancer	O
Hospital	O
KYCS2023	O
078	O
.	O

Registered	O
7	O
June	O
2023	O
.	O

Cancer	O
treatment	O
related	O
xerostomia	O
:	O
basics	O
therapeutics	O
and	O
future	O
perspectives	O
.	O

Xerostomia	O
generally	O
addressed	O
as	O
dry	O
mouth	O
poses	O
significant	O
challenges	O
to	O
patients	O
'	O
quality	O
of	O
life	O
particularly	O
in	O
the	O
context	O
of	O
cancer	O
treatment	O
.	O

Moreover	O
the	O
evidence	O
supporting	O
the	O
efficacy	O
of	O
proposed	O
interventions	O
remains	O
limited	O
and	O
subject	O
to	O
controversy	O
in	O
terms	O
of	O
safety	O
efficacy	O
and	O
optimal	O
protocol	O
.	O

This	O
review	O
provides	O
a	O
comprehensive	O
insight	O
into	O
cancer	O
treatment	O
related	O
xerostomia	O
underlying	O
its	O
pathophysiology	O
etiology	O
clinical	O
manifestation	O
and	O
therapeutic	O
options	O
providing	O
a	O
clinical	O
guide	O
for	O
clinicians	O
to	O
adopt	O
a	O
patient	O
tailored	O
approach	O
to	O
cancer	O
treatment	O
related	O
xerostomia	O
and	O
offering	O
vision	O
on	O
current	O
ongoing	O
and	O
future	O
studies	O
in	O
the	O
field	O
.	O

Effect	O
of	O
blood	O
oxidative	O
stress	O
indicators	O
on	O
oral	O
mucositis	O
in	O
patients	O
undergoing	O
radiotherapy	O
for	O
nasopharyngeal	O
carcinoma	O
.	O

OBJECTIVES	O
:	O
To	O
investigate	O
the	O
correlation	O
of	O
total	O
antioxidant	O
capacity	O
T	O
AOC	O
glutathione	O
peroxidase	O
GSH	O
PX	O
and	O
advanced	O
oxidized	O
protein	O
product	O
AOPP	O
levels	O
in	O
the	O
progression	O
of	O
oral	O
mucositis	O
OM	O
during	O
nasopharyngeal	O
carcinoma	O
NPC	O
radiotherapy	O
.	O

METHODS	O
:	O
This	O
prospective	O
study	O
included	O
102	O
patients	O
diagnosed	O
with	O
NPC	O
and	O
eligible	O
for	O
radiotherapy	O
indications	O
.	O

T	O
AOC	O
GSH	O
PX	O
and	O
AOPP	O
were	O
measured	O
before	O
treatment	O
T0	O
and	O
during	O
the	O
second	O
week	O
T1	O
fourth	O
week	O
T2	O
and	O
sixth	O
week	O
T3	O
of	O
the	O
intensity	O
modulated	O
radiation	O
therapy	O
IMRT	O
period	O
.	O

Patients	O
were	O
categorized	O
into	O
severe	O
OM	O
SOM	O
n	O
21	O
and	O
Non	O
SOM	O
n	O
81	O
groups	O
at	O
week	O
6	O
.	O

Serum	O
T	O
AOC	O
GSH	O
PX	O
and	O
AOPP	O
levels	O
were	O
compared	O
at	O
different	O
time	O
periods	O
.	O

The	O
trends	O
of	O
these	O
markers	O
in	O
the	O
two	O
groups	O
during	O
the	O
course	O
of	O
treatment	O
were	O
analyzed	O
.	O

Finally	O
stepwise	O
logistic	O
regression	O
was	O
conducted	O
to	O
analyze	O
the	O
risk	O
factors	O
for	O
SOM	O
in	O
NPC	O
patients	O
undergoing	O
IMRT	O
.	O

RESULTS	O
:	O
At	O
T1	O
and	O
T2	O
of	O
IMRT	O
T	O
AOC	O
and	O
GSH	O
PX	O
were	O
higher	O
in	O
the	O
SOM	O
group	O
than	O
in	O
the	O
Non	O
SOM	O
group	O
At	O
T3	O
T	O
AOC	O
and	O
GSH	O
PX	O
were	O
lower	O
in	O
the	O
SOM	O
group	O
than	O
in	O
the	O
Non	O
SOM	O
group	O
.	O

T	O
AOC	O
and	O
GSH	O
PX	O
had	O
similar	O
change	O
trends	O
in	O
Non	O
SOM	O
or	O
SOM	O
patients	O
i	O
.	O
e	O
.	O
T	O
AOC	O
levels	O
continued	O
to	O
increase	O
at	O
T2	O
and	O
decreased	O
at	O
T3	O
and	O
GSH	O
PX	O
increased	O
significantly	O
at	O
T2	O
and	O
decreased	O
at	O
T3	O
.	O

Of	O
interest	O
was	O
the	O
fact	O
that	O
T	O
AOC	O
and	O
GSH	O
PX	O
decreased	O
significantly	O
more	O
in	O
SOM	O
patients	O
than	O
in	O
Non	O
SOM	O
patients	O
at	O
T3	O
and	O
that	O
AOPP	O
levels	O
were	O
in	O
a	O
constant	O
state	O
of	O
increase	O
in	O
SOM	O
patients	O
.	O

Preoperative	O
hypoproteinemia	O
the	O
absence	O
of	O
oral	O
mucosal	O
protective	O
agents	O
and	O
the	O
receipt	O
of	O
synchronous	O
chemotherapy	O
were	O
independent	O
risk	O
factors	O
for	O
increasing	O
the	O
course	O
of	O
OM	O
in	O
patients	O
with	O
NPC	O
.	O

CONCLUSIONS	O
:	O
NPC	O
patients	O
undergoing	O
IMRT	O
exhibit	O
dynamic	O
alterations	O
in	O
blood	O
T	O
AOC	O
GSH	O
PX	O
and	O
AOPP	O
.	O

Notably	O
the	O
persistent	O
elevation	O
of	O
these	O
biomarkers	O
particularly	O
AOPP	O
is	O
significantly	O
associated	O
with	O
the	O
progression	O
of	O
SOM	O
in	O
these	O
patients	O
.	O

These	O
findings	O
underscore	O
the	O
involvement	O
of	O
oxidative	O
stress	O
imbalance	O
in	O
the	O
pathogenesis	O
of	O
oral	O
mucositis	O
following	O
IMRT	O
.	O

Clinical	O
efficacy	O
on	O
the	O
reconstruction	O
of	O
bone	O
defects	O
using	O
modular	O
hemipelvic	O
prosthesis	O
in	O
patients	O
with	O
pelvic	O
tumors	O
.	O

OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
clinical	O
efficacy	O
of	O
modular	O
hemipelvic	O
prosthesis	O
replacement	O
in	O
the	O
treatment	O
of	O
pelvic	O
tumors	O
and	O
the	O
relationship	O
between	O
postoperative	O
functional	O
recovery	O
and	O
the	O
position	O
deviation	O
of	O
the	O
hip	O
rotation	O
center	O
.	O

METHODS	O
:	O
A	O
retrospective	O
research	O
was	O
conducted	O
involving	O
56	O
patients	O
who	O
underwent	O
surgical	O
resection	O
of	O
pelvic	O
tumors	O
followed	O
by	O
modular	O
hemipelvic	O
prosthesis	O
reconstruction	O
between	O
2010	O
and	O
2016	O
.	O

Comprehensive	O
data	O
encompassing	O
preoperative	O
conditions	O
intraoperative	O
and	O
postoperative	O
follow	O
up	O
information	O
were	O
systematically	O
collected	O
.	O

Limb	O
function	O
was	O
evaluated	O
at	O
1	O
3	O
6	O
and	O
12	O
months	O
postoperatively	O
using	O
the	O
Musculoskeletal	O
Tumor	O
Society	O
Scores	O
MSTS	O
.	O

The	O
positional	O
deviation	O
of	O
the	O
hip	O
joint	O
'	O
s	O
rotational	O
center	O
was	O
quantified	O
.	O

Statistical	O
analyses	O
were	O
performed	O
utilizing	O
SPSS	O
26	O
.	O
0	O
software	O
.	O

RESULTS	O
:	O
All	O
surgical	O
interventions	O
were	O
successful	O
with	O
an	O
average	O
operation	O
time	O
of	O
268	O
.	O
82	O
42	O
.	O
17	O
min	O
and	O
mean	O
intraoperative	O
blood	O
loss	O
of	O
1086	O
.	O
64	O
538	O
.	O
28	O
ml	O
.	O

Postoperative	O
complications	O
were	O
noted	O
in	O
26	O
.	O
79	O
of	O
patients	O
predominantly	O
comprising	O
incision	O
related	O
issues	O
.	O

Hip	O
dislocation	O
was	O
documented	O
in	O
5	O
.	O
4	O
of	O
cases	O
while	O
seven	O
patients	O
experienced	O
prosthesis	O
loosening	O
or	O
fracture	O
during	O
follow	O
up	O
.	O

A	O
statistically	O
significant	O
improvement	O
in	O
MSTS	O
scores	O
was	O
observed	O
increasing	O
from	O
an	O
average	O
of	O
14	O
.	O
3	O
at	O
1	O
month	O
to	O
21	O
.	O
1	O
at	O
12	O
months	O
postoperatively	O
.	O

The	O
recorded	O
minor	O
deviations	O
in	O
the	O
position	O
of	O
the	O
prosthetic	O
hip	O
joint	O
'	O
s	O
rotational	O
center	O
did	O
not	O
exhibit	O
a	O
significant	O
correlation	O
with	O
functional	O
outcomes	O
.	O

The	O
observed	O
survival	O
rates	O
were	O
94	O
.	O
64	O
83	O
.	O
93	O
73	O
.	O
21	O
and	O
48	O
.	O
21	O
at	O
1	O
2	O
3	O
and	O
5	O
years	O
respectively	O
.	O

CONCLUSIONS	O
:	O
The	O
modular	O
hemipelvic	O
prosthesis	O
serves	O
as	O
an	O
effective	O
reconstructive	O
solution	O
for	O
bone	O
defects	O
resulting	O
from	O
pelvic	O
tumor	O
resection	O
facilitating	O
early	O
functional	O
rehabilitation	O
.	O

The	O
prosthesis	O
demonstrates	O
commendable	O
adaptability	O
and	O
mechanical	O
properties	O
with	O
a	O
low	O
incidence	O
of	O
complications	O
such	O
as	O
hip	O
dislocation	O
and	O
wound	O
related	O
issues	O
thereby	O
contributing	O
to	O
favorable	O
functional	O
recovery	O
of	O
the	O
affected	O
limb	O
.	O

Ferroptosis	O
and	O
the	O
tumor	O
microenvironment	O
.	O

Ferroptosis	O
is	O
a	O
type	O
of	O
regulated	O
cell	O
death	O
characterized	O
by	O
its	O
non	O
apoptotic	O
iron	O
dependent	O
and	O
oxidative	O
nature	O
.	O

Since	O
its	O
discovery	O
in	O
2012	O
extensive	O
research	O
has	O
demonstrated	O
its	O
pivotal	O
roles	O
in	O
tumorigenesis	O
metastasis	O
and	O
cancer	O
therapy	O
.	O

The	O
tumor	O
microenvironment	O
TME	O
is	O
a	O
complex	O
ecosystem	O
comprising	O
cancer	O
cells	O
non	O
cancer	O
cells	O
extracellular	O
matrix	O
metabolites	O
and	O
cytokines	O
.	O

Recent	O
studies	O
have	O
underscored	O
a	O
new	O
paradigm	O
in	O
which	O
non	O
cancer	O
cells	O
in	O
the	O
TME	O
such	O
as	O
immune	O
and	O
stromal	O
cells	O
also	O
play	O
significant	O
roles	O
in	O
regulating	O
tumor	O
progression	O
and	O
therapeutic	O
resistance	O
typically	O
through	O
complicated	O
crosstalk	O
with	O
cancer	O
cells	O
.	O

Notably	O
this	O
crosstalk	O
in	O
the	O
TME	O
were	O
partially	O
mediated	O
through	O
ferrotopsis	O
related	O
mechanisms	O
.	O

This	O
review	O
provides	O
a	O
comprehensive	O
and	O
systematic	O
summary	O
of	O
the	O
current	O
findings	O
concerning	O
the	O
roles	O
of	O
ferroptosis	O
in	O
the	O
TME	O
and	O
how	O
ferroptosis	O
mediated	O
TME	O
reprogramming	O
impacts	O
cancer	O
therapeutic	O
resistance	O
and	O
progression	O
.	O

Additionally	O
this	O
review	O
outlines	O
various	O
ferroptosis	O
related	O
therapeutic	O
strategies	O
aimed	O
at	O
targeting	O
the	O
TME	O
.	O

Complete	O
resection	O
of	O
a	O
giant	O
costal	O
chondrosarcoma	O
with	O
reconstruction	O
of	O
the	O
thoraco	O
abdominal	O
wall	O
:	O
a	O
case	O
report	O
.	O

BACKGROUND	O
:	O
Chondrosarcoma	O
primarily	O
occurs	O
in	O
the	O
pelvis	O
and	O
femur	O
with	O
occasional	O
cases	O
in	O
the	O
ribs	O
.	O

Surgical	O
resection	O
remains	O
the	O
main	O
treatment	O
method	O
for	O
costal	O
chondrosarcoma	O
.	O

However	O
complete	O
resection	O
often	O
leads	O
to	O
a	O
large	O
range	O
of	O
chest	O
wall	O
defects	O
and	O
a	O
challenging	O
reconstruction	O
.	O

CASE	O
PRESENTATION	O
:	O
A	O
49	O
year	O
old	O
female	O
patient	O
presented	O
with	O
progressive	O
swelling	O
of	O
the	O
right	O
chest	O
and	O
abdominal	O
wall	O
over	O
15	O
years	O
.	O

Chest	O
CT	O
revealed	O
a	O
20	O
.	O
1	O
x	O
15	O
.	O
6	O
x	O
13	O
.	O
7	O
cm	O
multilocular	O
cystic	O
solid	O
mass	O
with	O
internal	O
calcification	O
encircling	O
the	O
8th	O
to	O
12th	O
ribs	O
and	O
causing	O
elevation	O
of	O
the	O
right	O
diaphragm	O
.	O

Compression	O
of	O
the	O
liver	O
resulting	O
in	O
a	O
significant	O
reduction	O
in	O
volume	O
.	O

Based	O
on	O
an	O
ultrasound	O
guided	O
biopsy	O
chondrosarcoma	O
Grade	O
I	O
was	O
diagnosed	O
.	O

After	O
a	O
multi	O
disciplinary	O
discussion	O
we	O
performed	O
a	O
complete	O
resection	O
of	O
the	O
tumor	O
including	O
the	O
8th	O
to	O
12th	O
anterolateral	O
ribs	O
and	O
part	O
of	O
the	O
diaphragm	O
.	O

The	O
diaphragm	O
was	O
then	O
reconstructed	O
by	O
suturing	O
it	O
to	O
the	O
ribs	O
and	O
intercostal	O
muscles	O
at	O
the	O
resection	O
margin	O
.	O

The	O
thoraco	O
abdominal	O
wall	O
defects	O
were	O
reconstructed	O
with	O
a	O
polypropylene	O
mesh	O
.	O

Finally	O
we	O
excised	O
the	O
excess	O
skin	O
and	O
then	O
closed	O
the	O
incision	O
.	O

Histopathologic	O
diagnosis	O
was	O
chondrosarcoma	O
Grade	O
II	O
.	O

The	O
postoperative	O
course	O
was	O
uneventful	O
.	O

At	O
the	O
3	O
month	O
postoperative	O
follow	O
up	O
no	O
signs	O
of	O
recurrence	O
were	O
observed	O
.	O

CONCLUSIONS	O
:	O
Wide	O
en	O
bloc	O
resection	O
followed	O
by	O
reconstruction	O
using	O
polypropylene	O
mesh	O
is	O
feasible	O
and	O
cost	O
effective	O
for	O
costal	O
chondrosarcoma	O
with	O
limited	O
invasion	O
.	O

This	O
case	O
illustrates	O
the	O
importance	O
of	O
meticulous	O
preoperative	O
planning	O
and	O
multi	O
disciplinary	O
discussion	O
.	O

Crosstalk	O
of	O
pyroptosis	O
and	O
cytokine	O
in	O
the	O
tumor	O
microenvironment	O
:	O
from	O
mechanisms	O
to	O
clinical	O
implication	O
.	O

In	O
the	O
realm	O
of	O
cancer	O
research	O
the	O
tumor	O
microenvironment	O
TME	O
plays	O
a	O
crucial	O
role	O
in	O
tumor	O
initiation	O
and	O
progression	O
shaped	O
by	O
complex	O
interactions	O
between	O
cancer	O
cells	O
and	O
surrounding	O
non	O
cancerous	O
cells	O
.	O

Cytokines	O
as	O
essential	O
immunomodulatory	O
agents	O
are	O
secreted	O
by	O
various	O
cellular	O
constituents	O
within	O
the	O
TME	O
including	O
immune	O
cells	O
cancer	O
associated	O
fibroblasts	O
and	O
cancer	O
cells	O
themselves	O
.	O

These	O
cytokines	O
facilitate	O
intricate	O
communication	O
networks	O
that	O
significantly	O
influence	O
tumor	O
initiation	O
progression	O
metastasis	O
and	O
immune	O
suppression	O
.	O

Pyroptosis	O
contributes	O
to	O
TME	O
remodeling	O
by	O
promoting	O
the	O
release	O
of	O
pro	O
inflammatory	O
cytokines	O
and	O
sustaining	O
chronic	O
inflammation	O
impacting	O
processes	O
such	O
as	O
immune	O
escape	O
and	O
angiogenesis	O
.	O

However	O
challenges	O
remain	O
due	O
to	O
the	O
complex	O
interplay	O
among	O
cytokines	O
pyroptosis	O
and	O
the	O
TME	O
along	O
with	O
the	O
dual	O
effects	O
of	O
pyroptosis	O
on	O
cancer	O
progression	O
and	O
therapy	O
related	O
complications	O
like	O
cytokine	O
release	O
syndrome	O
.	O

Unraveling	O
these	O
complexities	O
could	O
facilitate	O
strategies	O
that	O
balance	O
inflammatory	O
responses	O
while	O
minimizing	O
tissue	O
damage	O
during	O
therapy	O
.	O

This	O
review	O
delves	O
into	O
the	O
complex	O
crosstalk	O
between	O
cytokines	O
pyroptosis	O
and	O
the	O
TME	O
elucidating	O
their	O
contribution	O
to	O
tumor	O
progression	O
and	O
metastasis	O
.	O

By	O
synthesizing	O
emerging	O
therapeutic	O
targets	O
and	O
innovative	O
technologies	O
concerning	O
TME	O
this	O
review	O
aims	O
to	O
provide	O
novel	O
insights	O
that	O
could	O
enhance	O
treatment	O
outcomes	O
for	O
cancer	O
patients	O
.	O

Enhancing	O
radiotherapy	O
in	O
triple	O
negative	O
breast	O
cancer	O
with	O
hesperetin	O
induced	O
ferroptosis	O
via	O
AURKA	O
targeting	O
nanocomposites	O
.	O

Triple	O
negative	O
breast	O
cancer	O
TNBC	O
is	O
an	O
aggressive	O
cancer	O
type	O
that	O
lacks	O
targeted	O
treatment	O
options	O
.	O

Ferroptosis	O
a	O
novel	O
therapeutic	O
strategy	O
induces	O
cell	O
death	O
by	O
disrupting	O
the	O
oxidative	O
reductive	O
balance	O
.	O

Hesperetin	O
a	O
potential	O
TNBC	O
therapeutic	O
drug	O
has	O
unidentified	O
regulatory	O
targets	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
potential	O
targets	O
of	O
hesperetin	O
in	O
TNBC	O
and	O
investigate	O
whether	O
the	O
nanocomposites	O
carrier	O
hesperetin	O
loaded	O
ferroptosis	O
inducing	O
nanocomposites	O
HFPN	O
which	O
activates	O
ferroptosis	O
can	O
enhance	O
the	O
anti	O
tumor	O
efficacy	O
of	O
hesperetin	O
.	O

Bioinformatics	O
methods	O
were	O
employed	O
to	O
screen	O
hesperetin	O
targets	O
in	O
TNBC	O
and	O
a	O
molecular	O
docking	O
model	O
between	O
hesperetin	O
and	O
the	O
core	O
target	O
aurora	O
kinase	O
A	O
AURKA	O
was	O
successfully	O
constructed	O
.	O

The	O
stability	O
and	O
anti	O
tumor	O
activity	O
of	O
HFPN	O
were	O
validated	O
in	O
cell	O
and	O
mouse	O
models	O
including	O
tumor	O
suppression	O
and	O
increased	O
radiation	O
sensitivity	O
.	O

These	O
results	O
suggest	O
that	O
HFPN	O
can	O
regulate	O
the	O
core	O
target	O
AURKA	O
in	O
TNBC	O
disrupt	O
tumor	O
oxidative	O
reductive	O
balance	O
promote	O
ferroptosis	O
in	O
tumor	O
cells	O
and	O
ultimately	O
enhance	O
the	O
effectiveness	O
of	O
radiation	O
therapy	O
for	O
TNBC	O
.	O

Correlates	O
associated	O
with	O
health	O
insurance	O
on	O
cervical	O
cancer	O
screening	O
in	O
Tanzania	O
:	O
a	O
comparison	O
between	O
the	O
insured	O
and	O
uninsured	O
women	O
using	O
demographic	O
and	O
health	O
survey	O
2022	O
.	O

BACKGROUND	O
:	O
Cervical	O
cancer	O
is	O
the	O
most	O
common	O
cancer	O
in	O
women	O
worldwide	O
.	O

This	O
cancer	O
affects	O
more	O
women	O
in	O
low	O
and	O
middle	O
income	O
countries	O
LMICs	O
including	O
Tanzania	O
.	O

Economic	O
losses	O
related	O
to	O
cervical	O
cancer	O
can	O
lead	O
to	O
a	O
serious	O
threat	O
to	O
collective	O
financial	O
well	O
being	O
and	O
increased	O
risk	O
for	O
the	O
households	O
to	O
catastrophic	O
health	O
expenditure	O
.	O

In	O
most	O
LMICs	O
out	O
of	O
pocket	O
OOP	O
payments	O
are	O
often	O
necessary	O
for	O
utilizing	O
medical	O
care	O
and	O
co	O
payments	O
of	O
health	O
insurance	O
to	O
access	O
some	O
of	O
the	O
health	O
services	O
.	O

This	O
study	O
aimed	O
to	O
assess	O
the	O
influence	O
of	O
health	O
insurance	O
among	O
women	O
on	O
access	O
to	O
cervical	O
cancer	O
screening	O
by	O
comparing	O
insured	O
and	O
non	O
insured	O
women	O
in	O
Tanzania	O
.	O

METHODS	O
:	O
This	O
study	O
used	O
secondary	O
data	O
collected	O
through	O
cross	O
sectional	O
design	O
during	O
the	O
Tanzania	O
Demographic	O
and	O
Health	O
Survey	O
2022	O
.	O

The	O
study	O
analyzed	O
the	O
information	O
from	O
a	O
total	O
sample	O
of	O
15	O
254	O
women	O
.	O

In	O
the	O
analysis	O
all	O
data	O
were	O
weighted	O
using	O
individual	O
women	O
sample	O
weight	O
to	O
account	O
for	O
complex	O
sampling	O
design	O
and	O
non	O
response	O
rate	O
.	O

The	O
analysis	O
of	O
this	O
study	O
used	O
univariate	O
bivariate	O
and	O
multivariable	O
logistic	O
regression	O
analysis	O
models	O
.	O

RESULTS	O
:	O
Our	O
analysis	O
revealed	O
that	O
only	O
7	O
.	O
01	O
of	O
women	O
were	O
screened	O
for	O
cervical	O
cancer	O
.	O

Health	O
insurance	O
coverage	O
was	O
statistically	O
significant	O
with	O
the	O
cervical	O
cancer	O
screening	O
.	O

This	O
means	O
that	O
the	O
insured	O
women	O
had	O
higher	O
odds	O
than	O
those	O
uninsured	O
women	O
for	O
both	O
the	O
crude	O
model	O
COR	O
3	O
.	O
12	O
CI	O
2	O
.	O
46	O
3	O
.	O
96	O
and	O
adjusted	O
models	O
AOR	O
1	O
.	O
75	O
CI	O
1	O
.	O
35	O
2	O
.	O
27	O
.	O

Age	O
education	O
level	O
currently	O
engaging	O
in	O
income	O
generating	O
jobs	O
and	O
those	O
who	O
visited	O
the	O
health	O
facility	O
at	O
least	O
once	O
in	O
12	O
months	O
influenced	O
the	O
cervical	O
cancer	O
screening	O
for	O
both	O
crude	O
and	O
adjusted	O
models	O
.	O

CONCLUSION	O
:	O
This	O
study	O
emphasizes	O
the	O
significance	O
of	O
various	O
factors	O
in	O
cervical	O
cancer	O
screening	O
in	O
Tanzania	O
.	O

These	O
factors	O
include	O
being	O
covered	O
by	O
health	O
insurance	O
socio	O
economic	O
status	O
and	O
education	O
.	O

Health	O
insurance	O
coverage	O
seems	O
to	O
be	O
a	O
predictor	O
of	O
accessing	O
health	O
services	O
including	O
screening	O
for	O
cervical	O
cancer	O
.	O

Therefore	O
the	O
government	O
should	O
take	O
these	O
factors	O
especially	O
health	O
insurance	O
into	O
account	O
when	O
formulating	O
policies	O
and	O
making	O
decisions	O
to	O
enhance	O
access	O
to	O
cervical	O
cancer	O
screening	O
for	O
women	O
in	O
Tanzania	O
including	O
fasterning	O
an	O
ongoing	O
process	O
of	O
establishing	O
a	O
prepayment	O
scheme	O
of	O
mandatory	O
health	O
insurance	O
for	O
all	O
citizens	O
.	O

Comparison	O
of	O
proximal	O
gastrectomy	O
with	O
tubular	O
esophagogastric	O
anastomosis	O
and	O
total	O
gastrectomy	O
with	O
Roux	O
en	O
Y	O
reconstruction	O
in	O
the	O
treatment	O
of	O
adenocarcinoma	O
of	O
the	O
esophagogastric	O
junction	O
of	O
Siewert	O
type	O
II	O
III	O
at	O
stage	O
II	O
.	O

BACKGROUND	O
:	O
Tubular	O
anastomosis	O
is	O
commonly	O
used	O
in	O
proximal	O
gastrectomy	O
however	O
its	O
use	O
in	O
stage	O
II	O
esophagogastric	O
conjugate	O
cancer	O
is	O
currently	O
unclear	O
.	O

In	O
this	O
study	O
we	O
investigated	O
the	O
short	O
and	O
long	O
term	O
clinical	O
outcomes	O
of	O
Siewert	O
II	O
III	O
adenocarcinoma	O
of	O
the	O
esophagogastric	O
junction	O
after	O
modified	O
proximal	O
gastrectomy	O
with	O
tubular	O
esophagogastric	O
anastomosis	O
compared	O
with	O
total	O
gastrectomy	O
with	O
Roux	O
en	O
Y	O
reconstruction	O
.	O

METHODS	O
:	O
We	O
collected	O
the	O
clinical	O
data	O
of	O
patients	O
who	O
underwent	O
proximal	O
gastrectomy	O
tubular	O
esophagogastric	O
anastomosis	O
PG	O
TEA	O
and	O
total	O
gastrectomy	O
Roux	O
en	O
Y	O
reconstruction	O
TG	O
RY	O
from	O
October	O
2015	O
to	O
October	O
2018	O
.	O

The	O
clinical	O
characteristics	O
postoperative	O
quality	O
of	O
life	O
nutritional	O
status	O
and	O
long	O
term	O
survival	O
outcomes	O
of	O
the	O
two	O
groups	O
were	O
compared	O
.	O

RESULTS	O
:	O
There	O
were	O
43	O
patients	O
in	O
the	O
PG	O
TEA	O
group	O
and	O
80	O
patients	O
in	O
the	O
TG	O
RY	O
group	O
and	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
baseline	O
data	O
of	O
the	O
groups	O
.	O

The	O
operation	O
time	O
of	O
the	O
PG	O
TEA	O
group	O
was	O
shorter	O
there	O
was	O
less	O
intraoperative	O
bleeding	O
and	O
the	O
feeding	O
time	O
was	O
earlier	O
which	O
was	O
conducive	O
to	O
postoperative	O
recovery	O
.	O

Reflux	O
esophagitis	O
was	O
more	O
evident	O
in	O
the	O
PG	O
TEA	O
group	O
than	O
in	O
the	O
TG	O
RY	O
group	O
and	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
incidence	O
of	O
anastomotic	O
ulcers	O
or	O
other	O
complications	O
.	O

Three	O
months	O
after	O
surgery	O
the	O
nutritional	O
status	O
of	O
the	O
PG	O
TEA	O
group	O
was	O
better	O
than	O
the	O
TG	O
RY	O
group	O
.	O

By	O
the	O
6th	O
postoperative	O
month	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
.	O

Regarding	O
quality	O
of	O
life	O
the	O
PG	O
TEA	O
group	O
was	O
superior	O
to	O
the	O
TG	O
RY	O
group	O
in	O
terms	O
of	O
diarrhea	O
and	O
dumping	O
syndrome	O
.	O

In	O
addition	O
the	O
PG	O
TEA	O
group	O
had	O
higher	O
satisfaction	O
with	O
daily	O
life	O
and	O
higher	O
quality	O
meals	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
overall	O
survival	O
between	O
the	O
two	O
groups	O
.	O

CONCLUSIONS	O
:	O
Proximal	O
gastrectomy	O
tubular	O
gastroesophageal	O
anastomosis	O
is	O
a	O
surgical	O
procedure	O
for	O
stage	O
II	O
Siewert	O
type	O
II	O
and	O
III	O
AEG	O
.	O

It	O
achieves	O
similar	O
clinical	O
outcomes	O
to	O
those	O
after	O
total	O
gastrectomy	O
and	O
can	O
be	O
further	O
applied	O
in	O
the	O
clinic	O
.	O

Esophageal	O
ESD	O
Training	O
Perspective	O
of	O
West	O
vs	O
.	O
East	O
.	O

PURPOSE	O
OF	O
REVIEW	O
:	O
Esophageal	O
cancer	O
is	O
one	O
of	O
the	O
most	O
common	O
cancers	O
in	O
the	O
world	O
and	O
carries	O
a	O
poor	O
prognosis	O
.	O

While	O
esophagectomy	O
poses	O
considerable	O
mortality	O
and	O
morbidity	O
risks	O
endoscopic	O
resection	O
can	O
provide	O
a	O
safer	O
and	O
less	O
invasive	O
alternative	O
.	O

RECENT	O
FINDINGS	O
:	O
Endoscopic	O
resection	O
therapy	O
has	O
allowed	O
a	O
less	O
invasive	O
approach	O
with	O
comparable	O
outcomes	O
to	O
esophagectomy	O
.	O

EMR	O
is	O
considered	O
safe	O
and	O
requires	O
less	O
intensive	O
training	O
yet	O
it	O
does	O
not	O
offer	O
complete	O
histopathological	O
assessment	O
due	O
to	O
the	O
nature	O
of	O
piecemeal	O
resection	O
for	O
larger	O
lesions	O
.	O

Alternatively	O
ESD	O
offers	O
an	O
R0	O
resection	O
therefore	O
allowing	O
precise	O
histopathological	O
evaluation	O
.	O

Training	O
in	O
ESD	O
is	O
essential	O
however	O
a	O
uniform	O
training	O
model	O
has	O
not	O
been	O
agreed	O
upon	O
.	O

The	O
Japanese	O
apprenticeship	O
training	O
model	O
has	O
proven	O
effective	O
with	O
promising	O
training	O
outcomes	O
from	O
the	O
Eastern	O
experience	O
.	O

In	O
the	O
West	O
a	O
comprehensive	O
training	O
model	O
through	O
a	O
combination	O
of	O
apprenticeship	O
with	O
progressive	O
exposure	O
including	O
ex	O
vivo	O
and	O
live	O
animal	O
hands	O
on	O
training	O
could	O
be	O
the	O
optimal	O
approach	O
.	O

Different	O
methods	O
of	O
ESD	O
training	O
are	O
currently	O
available	O
all	O
of	O
which	O
aim	O
to	O
provide	O
the	O
experience	O
needed	O
to	O
perform	O
safe	O
ESD	O
.	O

Despite	O
the	O
differences	O
in	O
training	O
styles	O
between	O
the	O
East	O
and	O
the	O
West	O
a	O
modified	O
apprenticeship	O
model	O
could	O
potentially	O
result	O
in	O
more	O
effective	O
and	O
better	O
training	O
outcomes	O
.	O

The	O
currently	O
available	O
technologies	O
provide	O
the	O
environment	O
to	O
enhance	O
ESD	O
training	O
.	O

Long	O
term	O
tumor	O
control	O
following	O
gamma	O
knife	O
radiosurgery	O
of	O
recurrent	O
or	O
residual	O
pituitary	O
adenomas	O
:	O
a	O
population	O
based	O
cohort	O
study	O
.	O

BACKGROUND	O
:	O
Pituitary	O
adenomas	O
PAs	O
often	O
require	O
adjuvant	O
Gamma	O
Knife	O
radiosurgery	O
GKRS	O
due	O
to	O
partial	O
resection	O
or	O
postoperative	O
recurrence	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
long	O
term	O
efficacy	O
of	O
GKRS	O
for	O
such	O
cases	O
.	O

METHODS	O
:	O
Population	O
based	O
observational	O
cohort	O
study	O
of	O
patients	O
who	O
underwent	O
GKRS	O
for	O
postoperative	O
residual	O
or	O
recurrent	O
PAs	O
between	O
1999	O
and	O
2020	O
.	O

We	O
assessed	O
long	O
term	O
progression	O
free	O
survival	O
PFS	O
identified	O
predictors	O
of	O
tumor	O
growth	O
and	O
documented	O
adverse	O
radiation	O
events	O
AREs	O
.	O

RESULTS	O
:	O
147	O
patients	O
were	O
included	O
with	O
a	O
median	O
follow	O
up	O
time	O
of	O
8	O
.	O
1	O
years	O
.	O

Following	O
GKRS	O
the	O
5	O
year	O
and	O
10	O
year	O
PFS	O
was	O
86	O
and	O
68	O
respectively	O
with	O
a	O
median	O
PFS	O
of	O
18	O
.	O
7	O
years	O
.	O

Somatotrophic	O
adenomas	O
showed	O
a	O
significantly	O
lower	O
risk	O
of	O
tumor	O
progression	O
in	O
the	O
regression	O
analysis	O
OR	O
0	O
.	O
11	O
p	O
0	O
.	O
003	O
.	O

Hypopituitarism	O
was	O
the	O
most	O
common	O
ARE	O
affecting	O
32	O
of	O
patients	O
.	O

CONCLUSION	O
:	O
GKRS	O
is	O
an	O
effective	O
treatment	O
option	O
for	O
recurrent	O
or	O
residual	O
PAs	O
offering	O
substantial	O
long	O
term	O
control	O
.	O

However	O
the	O
risk	O
for	O
AREs	O
particularly	O
hypopituitarism	O
is	O
not	O
negligeable	O
.	O

Primary	O
intracranial	O
myoepithelioma	O
in	O
a	O
child	O
.	O

Myoepitheliomal	O
tumours	O
associated	O
with	O
the	O
salivary	O
glands	O
and	O
certain	O
soft	O
tissue	O
sites	O
are	O
unusually	O
encountered	O
in	O
the	O
central	O
nervous	O
system	O
CNS	O
.	O

In	O
the	O
brain	O
although	O
the	O
most	O
common	O
location	O
is	O
the	O
Sella	O
other	O
areas	O
can	O
infrequently	O
be	O
involved	O
.	O

Such	O
intracranial	O
lesions	O
are	O
exceptionally	O
rare	O
in	O
children	O
.	O

We	O
report	O
a	O
case	O
of	O
CNS	O
myoepithelioma	O
in	O
a	O
child	O
harbouring	O
an	O
intra	O
axial	O
posterior	O
frontal	O
mass	O
and	O
briefly	O
review	O
the	O
relevant	O
literature	O
.	O

This	O
8	O
year	O
old	O
boy	O
presenting	O
with	O
features	O
of	O
intracranial	O
pressure	O
effects	O
underwent	O
excision	O
of	O
the	O
lesion	O
and	O
the	O
diagnosis	O
was	O
confirmed	O
with	O
histopathology	O
and	O
immunohistochemical	O
studies	O
.	O

He	O
had	O
a	O
good	O
clinical	O
outcome	O
.	O

Unusually	O
primary	O
intracranial	O
myoepitheliomas	O
can	O
manifest	O
as	O
cerebral	O
parenchymal	O
mass	O
lesions	O
.	O

Although	O
these	O
are	O
usually	O
a	O
pathological	O
surprise	O
the	O
index	O
case	O
and	O
available	O
limited	O
reports	O
highlight	O
the	O
need	O
for	O
an	O
awareness	O
of	O
such	O
uncommon	O
paediatric	O
tumours	O
both	O
in	O
an	O
intra	O
axial	O
and	O
dural	O
location	O
.	O

The	O
dysadherin	O
MMP9	O
axis	O
modifies	O
the	O
extracellular	O
matrix	O
to	O
accelerate	O
colorectal	O
cancer	O
progression	O
.	O

The	O
dynamic	O
alteration	O
of	O
the	O
tumor	O
microenvironment	O
TME	O
serves	O
as	O
a	O
driving	O
force	O
behind	O
the	O
progression	O
and	O
metastasis	O
of	O
colorectal	O
cancer	O
CRC	O
.	O

Within	O
the	O
intricate	O
TME	O
a	O
pivotal	O
player	O
is	O
the	O
extracellular	O
matrix	O
ECM	O
where	O
modifications	O
in	O
components	O
degradation	O
and	O
stiffness	O
are	O
considered	O
critical	O
factors	O
in	O
tumor	O
development	O
.	O

In	O
this	O
study	O
we	O
find	O
that	O
the	O
membrane	O
glycoprotein	O
dysadherin	O
directly	O
targets	O
matrix	O
metalloprotease	O
9	O
MMP9	O
initiating	O
ECM	O
remodeling	O
within	O
the	O
TME	O
and	O
amplifying	O
cancer	O
progression	O
.	O

Mechanistically	O
the	O
dysadherin	O
MMP9	O
axis	O
not	O
only	O
enhances	O
CRC	O
cell	O
invasiveness	O
and	O
ECM	O
proteolytic	O
activity	O
but	O
also	O
activates	O
cancer	O
associated	O
fibroblasts	O
orchestrating	O
the	O
restructuring	O
of	O
the	O
ECM	O
through	O
the	O
synthesis	O
of	O
its	O
components	O
in	O
human	O
CRC	O
cells	O
patient	O
samples	O
and	O
mouse	O
models	O
.	O

Notably	O
disruption	O
of	O
ECM	O
reorganization	O
by	O
dysadherin	O
knockout	O
results	O
in	O
a	O
discernible	O
reduction	O
in	O
the	O
immunosuppressive	O
and	O
proangiogenic	O
milieu	O
in	O
a	O
humanized	O
mouse	O
model	O
.	O

Intriguingly	O
these	O
effects	O
are	O
reversed	O
upon	O
the	O
overexpression	O
of	O
MMP9	O
highlighting	O
the	O
intricate	O
and	O
pivotal	O
role	O
of	O
the	O
dysadherin	O
MMP9	O
axis	O
in	O
shaping	O
the	O
development	O
of	O
a	O
malignant	O
TME	O
.	O

Therefore	O
our	O
findings	O
not	O
only	O
highlight	O
that	O
dysadherin	O
contributes	O
to	O
CRC	O
progression	O
by	O
influencing	O
the	O
TME	O
through	O
ECM	O
remodeling	O
but	O
also	O
suggest	O
that	O
dysadherin	O
may	O
be	O
a	O
potential	O
therapeutic	O
target	O
for	O
CRC	O
.	O

The	O
roles	O
of	O
periostin	O
derived	O
from	O
cancer	O
associated	O
fibroblasts	O
in	O
tumor	O
progression	O
and	O
treatment	O
response	O
.	O

Periostin	O
POSTN	O
a	O
matricellular	O
protein	O
predominantly	O
secreted	O
by	O
cancer	O
associated	O
fibroblasts	O
CAFs	O
has	O
emerged	O
as	O
a	O
key	O
regulator	O
of	O
cancer	O
progression	O
and	O
therapy	O
response	O
.	O

This	O
review	O
provides	O
an	O
overview	O
of	O
recent	O
findings	O
regarding	O
the	O
diverse	O
roles	O
of	O
periostin	O
in	O
cancer	O
therapy	O
and	O
its	O
potential	O
as	O
a	O
therapeutic	O
target	O
.	O

Studies	O
have	O
elucidated	O
periostin	O
'	O
s	O
involvement	O
in	O
tumorigenesis	O
including	O
tumor	O
growth	O
metastasis	O
chemotherapy	O
resistance	O
and	O
modulation	O
of	O
the	O
tumor	O
microenvironment	O
TME	O
.	O

CAFs	O
periostin	O
play	O
a	O
central	O
role	O
in	O
shaping	O
the	O
TME	O
by	O
remodeling	O
the	O
extracellular	O
matrix	O
ECM	O
and	O
promoting	O
immune	O
evasion	O
thus	O
promoting	O
tumor	O
cell	O
survival	O
and	O
dissemination	O
.	O

Elevated	O
periostin	O
expression	O
has	O
been	O
correlated	O
with	O
poor	O
prognosis	O
across	O
multiple	O
cancer	O
types	O
suggesting	O
its	O
utility	O
as	O
a	O
prognostic	O
biomarker	O
.	O

Periostin	O
has	O
been	O
implicated	O
in	O
mediating	O
resistance	O
to	O
chemotherapy	O
with	O
CAFs	O
periostin	O
establishing	O
a	O
pro	O
tumorigenic	O
niche	O
that	O
confers	O
protection	O
to	O
cancer	O
cells	O
against	O
cytotoxic	O
therapies	O
.	O

Targeting	O
periostin	O
or	O
its	O
downstream	O
effectors	O
presents	O
a	O
promising	O
strategy	O
to	O
overcome	O
therapy	O
resistance	O
and	O
enhance	O
treatment	O
efficacy	O
.	O

While	O
significant	O
progress	O
has	O
been	O
made	O
in	O
understanding	O
the	O
biological	O
functions	O
of	O
periostin	O
in	O
cancer	O
gaps	O
persist	O
in	O
elucidating	O
its	O
precise	O
mechanisms	O
of	O
action	O
and	O
clinical	O
relevance	O
.	O

Future	O
research	O
should	O
focus	O
on	O
deciphering	O
the	O
signaling	O
pathways	O
and	O
molecular	O
interactions	O
underlying	O
periostin	O
mediated	O
effects	O
in	O
the	O
TME	O
.	O

Prospective	O
clinical	O
studies	O
are	O
warranted	O
to	O
evaluate	O
periostin	O
as	O
a	O
predictive	O
biomarker	O
and	O
therapeutic	O
target	O
in	O
cancer	O
patients	O
.	O

Recent	O
novelties	O
in	O
research	O
and	O
management	O
of	O
cerebrospinal	O
cavernous	O
malformations	O
.	O

In	O
recent	O
years	O
knowledge	O
about	O
cerebrospinal	O
cavernomas	O
has	O
grown	O
considerably	O
leading	O
to	O
the	O
development	O
of	O
initial	O
guidelines	O
and	O
treatment	O
recommendations	O
.	O

However	O
due	O
to	O
the	O
rarity	O
and	O
heterogeneity	O
of	O
the	O
disease	O
the	O
level	O
of	O
evidence	O
remains	O
limited	O
leaving	O
many	O
questions	O
unanswered	O
and	O
subject	O
to	O
ongoing	O
debate	O
.	O

Therefore	O
an	O
up	O
to	O
date	O
review	O
of	O
this	O
field	O
'	O
s	O
latest	O
developments	O
and	O
controversies	O
is	O
reasonable	O
.	O

Lack	O
of	O
WDFY4	O
leads	O
to	O
impaired	O
immune	O
response	O
and	O
poor	O
cancer	O
prognosis	O
.	O

WDFY4	O
plays	O
an	O
essential	O
role	O
in	O
the	O
immune	O
system	O
by	O
regulating	O
B	O
cell	O
growth	O
and	O
development	O
and	O
participating	O
in	O
antigen	O
processing	O
during	O
cross	O
presentation	O
.	O

WDFY4	O
is	O
closely	O
related	O
to	O
asthma	O
and	O
systemic	O
lupus	O
erythematosus	O
however	O
its	O
role	O
in	O
cancer	O
remains	O
unclear	O
.	O

The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
use	O
bioinformatics	O
to	O
determine	O
whether	O
abnormal	O
expression	O
of	O
WDFY4	O
is	O
a	O
risk	O
factor	O
for	O
cancer	O
and	O
to	O
preliminarily	O
analyze	O
the	O
ways	O
in	O
which	O
WDFY4	O
affects	O
cancer	O
through	O
experiments	O
.	O

R	O
language	O
packages	O
and	O
bioinformatic	O
database	O
were	O
used	O
to	O
mine	O
the	O
potential	O
carcinogenic	O
effect	O
of	O
WDFY4	O
and	O
analyze	O
the	O
differential	O
WDFY4	O
expression	O
in	O
cancer	O
gene	O
mutations	O
different	O
tumor	O
prognoses	O
immune	O
cell	O
infiltration	O
tumor	O
microenvironment	O
and	O
DNA	O
methylation	O
correlation	O
.	O

H1975	O
and	O
A549	O
cell	O
lines	O
were	O
infected	O
with	O
lentiviruses	O
to	O
overexpress	O
WDFY4	O
and	O
the	O
effect	O
of	O
WDFY4	O
on	O
the	O
activity	O
proliferation	O
apoptosis	O
and	O
cell	O
cycle	O
of	O
lung	O
cancer	O
cells	O
was	O
analyzed	O
.	O

WDFY4	O
was	O
differentially	O
expressed	O
in	O
human	O
tumors	O
in	O
unpaired	O
and	O
paired	O
samples	O
.	O

The	O
differential	O
expression	O
of	O
WDFY4	O
in	O
unpaired	O
and	O
paired	O
or	O
protein	O
samples	O
from	O
the	O
Clinical	O
Proteome	O
Tumor	O
Analysis	O
Consortium	O
of	O
eight	O
cancers	O
was	O
consistent	O
.	O

WDFY4	O
methylation	O
was	O
downregulated	O
in	O
17	O
cancer	O
types	O
and	O
caused	O
prognostic	O
differences	O
in	O
different	O
directions	O
in	O
some	O
cancers	O
.	O

WDFY4	O
overexpression	O
significantly	O
inhibited	O
the	O
activity	O
and	O
proliferation	O
of	O
lung	O
cancer	O
cell	O
lines	O
promoted	O
apoptosis	O
and	O
caused	O
cell	O
cycle	O
arrest	O
.	O

Differential	O
WDFY4	O
expression	O
in	O
cancers	O
leads	O
to	O
differences	O
in	O
the	O
prognosis	O
of	O
various	O
cancers	O
.	O

WDFY4	O
can	O
be	O
an	O
independent	O
prognostic	O
factor	O
for	O
glioma	O
KIRC	O
and	O
LUSC	O
.	O

LAG	O
3	O
An	O
incompletely	O
understood	O
target	O
in	O
cancer	O
therapy	O
.	O

LAG	O
3	O
is	O
a	O
member	O
of	O
the	O
immunoglobulin	O
superfamily	O
expressed	O
on	O
activated	O
T	O
cells	O
but	O
also	O
on	O
other	O
immune	O
cells	O
.	O

It	O
has	O
significant	O
homology	O
to	O
CD4	O
.	O

Both	O
molecules	O
have	O
four	O
extracellular	O
Ig	O
like	O
domains	O
with	O
similar	O
structural	O
motifs	O
but	O
the	O
sequence	O
identity	O
between	O
LAG	O
3	O
and	O
CD4	O
is	O
low	O
.	O

Furthermore	O
unlike	O
CD4	O
LAG	O
3	O
restrains	O
T	O
cell	O
responses	O
and	O
antibodies	O
targeting	O
this	O
receptor	O
are	O
emerging	O
drugs	O
in	O
cancer	O
immunotherapy	O
.	O

A	O
combination	O
of	O
LAG	O
3	O
and	O
PD	O
1	O
antibodies	O
has	O
already	O
been	O
approved	O
for	O
the	O
treatment	O
of	O
metastatic	O
melanoma	O
.	O

Despite	O
this	O
success	O
its	O
biology	O
is	O
still	O
not	O
well	O
understood	O
.	O

Here	O
we	O
summarize	O
the	O
current	O
knowledge	O
on	O
expression	O
ligands	O
and	O
function	O
of	O
LAG	O
3	O
.	O

We	O
point	O
to	O
the	O
differences	O
between	O
LAG	O
3	O
and	O
other	O
inhibitory	O
immune	O
checkpoints	O
and	O
describe	O
obstacles	O
to	O
study	O
the	O
role	O
of	O
this	O
receptor	O
in	O
T	O
cell	O
activation	O
processes	O
.	O

Finally	O
we	O
discuss	O
future	O
directions	O
for	O
scientific	O
efforts	O
to	O
come	O
to	O
a	O
more	O
complete	O
understanding	O
of	O
the	O
biology	O
of	O
this	O
eminent	O
immune	O
checkpoint	O
.	O

Oxidative	O
stress	O
drives	O
endometrial	O
fibrosis	O
via	O
TGF	O
beta1	O
MAPK	O
signaling	O
pathway	O
in	O
breast	O
cancer	O
.	O

Breast	O
cancer	O
patients	O
have	O
high	O
serum	O
reactive	O
oxygen	O
species	O
ROS	O
levels	O
which	O
exert	O
toxicity	O
on	O
the	O
ovary	O
.	O

However	O
it	O
is	O
still	O
unclear	O
whether	O
tumor	O
derived	O
ROS	O
play	O
a	O
role	O
in	O
endometrial	O
development	O
and	O
function	O
in	O
breast	O
cancer	O
.	O

Breast	O
cancer	O
patients	O
and	O
healthy	O
controls	O
were	O
recruited	O
and	O
endometrial	O
thickness	O
was	O
measured	O
by	O
transvaginal	O
ultrasound	O
TVUS	O
.	O

Xenograft	O
tumors	O
of	O
the	O
breast	O
cancer	O
cell	O
line	O
MDA	O
MB	O
231	O
in	O
a	O
female	O
BALB	O
c	O
nude	O
mice	O
model	O
were	O
established	O
and	O
the	O
therapeutic	O
mechanism	O
of	O
vitamin	O
C	O
VC	O
was	O
investigated	O
on	O
uterine	O
pathology	O
in	O
vivo	O
and	O
the	O
contribution	O
of	O
co	O
culture	O
of	O
breast	O
cancer	O
cell	O
and	O
endometrial	O
epithelial	O
cell	O
on	O
this	O
process	O
was	O
examined	O
in	O
vitro	O
.	O

Median	O
thickness	O
in	O
endometria	O
was	O
lower	O
in	O
breast	O
cancer	O
patients	O
and	O
tumor	O
bearing	O
mice	O
compared	O
to	O
controls	O
.	O

A	O
gene	O
signature	O
of	O
uteri	O
in	O
tumor	O
bearing	O
mice	O
demonstrated	O
differential	O
expression	O
of	O
genes	O
DEGs	O
regulating	O
extracellular	O
matrix	O
ECM	O
and	O
epithelial	O
mesenchymal	O
transition	O
EMT	O
and	O
activation	O
of	O
TGF	O
beta	O
and	O
MAPK	O
signaling	O
pathways	O
.	O

In	O
addition	O
ROS	O
EMT	O
and	O
ECM	O
related	O
protein	O
levels	O
were	O
enhanced	O
in	O
uteri	O
in	O
tumor	O
bearing	O
mice	O
as	O
well	O
as	O
in	O
Ishikawa	O
cells	O
which	O
were	O
co	O
cultured	O
with	O
MDA	O
MB	O
231	O
cells	O
compared	O
to	O
controls	O
.	O

Supplementation	O
with	O
VC	O
reduced	O
endometrial	O
damage	O
inhibited	O
the	O
EMT	O
process	O
and	O
collagen	O
deposition	O
and	O
maintained	O
better	O
histologic	O
architecture	O
of	O
uteri	O
in	O
tumor	O
bearing	O
mice	O
via	O
inactivation	O
of	O
the	O
TGF	O
beta1	O
p38MAPK	O
pathway	O
.	O

In	O
women	O
with	O
breast	O
cancer	O
oxidative	O
stress	O
in	O
the	O
endometrium	O
results	O
in	O
a	O
fibrotic	O
response	O
as	O
a	O
consequence	O
of	O
EMT	O
.	O

VC	O
could	O
alleviate	O
endometrial	O
fibrosis	O
via	O
TGF	O
beta1	O
p38MAPK	O
pathway	O
and	O
provide	O
new	O
predictive	O
and	O
therapeutic	O
targets	O
for	O
fertility	O
preservation	O
in	O
younger	O
breast	O
cancer	O
patients	O
.	O

Burden	O
of	O
biliary	O
tract	O
carcinoma	O
in	O
China	O
1990	O
2021	O
:	O
Findings	O
from	O
the	O
2021	O
Global	O
Burden	O
of	O
Disease	O
Study	O
.	O

Biliary	O
tract	O
carcinoma	O
BTC	O
is	O
a	O
group	O
of	O
malignant	O
tumors	O
that	O
originate	O
in	O
the	O
digestive	O
system	O
and	O
occurs	O
with	O
a	O
high	O
incidence	O
in	O
China	O
.	O

Few	O
consistent	O
and	O
comparable	O
assessments	O
of	O
BTC	O
disease	O
burden	O
have	O
been	O
conducted	O
at	O
national	O
or	O
subnational	O
levels	O
and	O
little	O
is	O
known	O
about	O
the	O
demographic	O
temporal	O
and	O
geographic	O
patterns	O
of	O
epidemiological	O
characteristics	O
and	O
disease	O
burden	O
of	O
BTC	O
in	O
China	O
.	O

The	O
incidence	O
mortality	O
disability	O
adjusted	O
life	O
years	O
DALYs	O
years	O
of	O
life	O
lost	O
YLLs	O
due	O
to	O
premature	O
death	O
and	O
years	O
lived	O
with	O
disability	O
YLDs	O
of	O
BTC	O
were	O
comprehensively	O
examined	O
by	O
age	O
sex	O
and	O
calendar	O
year	O
in	O
the	O
Chinese	O
population	O
using	O
the	O
methodological	O
framework	O
and	O
analytical	O
strategies	O
used	O
for	O
the	O
2021	O
Global	O
Burden	O
of	O
Disease	O
study	O
.	O

All	O
age	O
incidence	O
increased	O
from	O
17	O
077	O
to	O
51	O
720	O
between	O
1990	O
and	O
2021	O
and	O
the	O
age	O
standardized	O
incidence	O
rate	O
rose	O
by	O
13	O
.	O
62	O
all	O
age	O
deaths	O
increased	O
from	O
17	O
251	O
to	O
37	O
833	O
but	O
the	O
age	O
standardized	O
mortality	O
rate	O
fell	O
by	O
nearly	O
one	O
fifth	O
.	O

The	O
DALYs	O
rose	O
by	O
89	O
.	O
57	O
while	O
the	O
age	O
standardized	O
DALY	O
rate	O
fell	O
by	O
23	O
.	O
24	O
.	O

Variations	O
of	O
the	O
tendencies	O
in	O
BTC	O
burden	O
were	O
found	O
between	O
sexes	O
and	O
age	O
groups	O
.	O

Data	O
for	O
each	O
provincial	O
region	O
indicate	O
that	O
coastal	O
eastern	O
provincial	O
regions	O
have	O
higher	O
incidence	O
and	O
YLD	O
levels	O
whereas	O
northern	O
provincial	O
regions	O
have	O
higher	O
mortality	O
DALY	O
and	O
YLL	O
levels	O
.	O

The	O
proportions	O
of	O
DALYs	O
attributable	O
to	O
high	O
body	O
mass	O
index	O
BMI	O
illustrate	O
the	O
growing	O
attribution	O
obesity	O
has	O
made	O
and	O
high	O
BMI	O
usually	O
puts	O
more	O
burden	O
on	O
northern	O
provincial	O
regions	O
.	O

These	O
results	O
provide	O
evidence	O
to	O
support	O
precise	O
targeted	O
and	O
customed	O
public	O
health	O
strategies	O
aimed	O
at	O
enhancing	O
biliary	O
tract	O
health	O
among	O
the	O
Chinese	O
population	O
.	O

Latent	O
Archetypes	O
of	O
the	O
Spatial	O
Patterns	O
of	O
Cancer	O
.	O

The	O
cancer	O
atlas	O
edited	O
by	O
several	O
countries	O
is	O
the	O
main	O
resource	O
for	O
the	O
analysis	O
of	O
the	O
geographic	O
variation	O
of	O
cancer	O
risk	O
.	O

Correlating	O
the	O
observed	O
spatial	O
patterns	O
with	O
known	O
or	O
hypothesized	O
risk	O
factors	O
is	O
time	O
consuming	O
work	O
for	O
epidemiologists	O
who	O
need	O
to	O
deal	O
with	O
each	O
cancer	O
separately	O
breaking	O
down	O
the	O
patterns	O
according	O
to	O
sex	O
and	O
race	O
.	O

The	O
recent	O
literature	O
has	O
proposed	O
to	O
study	O
more	O
than	O
one	O
cancer	O
simultaneously	O
looking	O
for	O
common	O
spatial	O
risk	O
factors	O
.	O

However	O
this	O
previous	O
work	O
has	O
two	O
constraints	O
:	O
they	O
consider	O
only	O
a	O
very	O
small	O
2	O
4	O
number	O
of	O
cancers	O
previously	O
known	O
to	O
share	O
risk	O
factors	O
.	O

In	O
this	O
article	O
we	O
propose	O
an	O
exploratory	O
method	O
to	O
search	O
for	O
latent	O
spatial	O
risk	O
factors	O
of	O
a	O
large	O
number	O
of	O
supposedly	O
unrelated	O
cancers	O
.	O

The	O
method	O
is	O
based	O
on	O
the	O
singular	O
value	O
decomposition	O
and	O
nonnegative	O
matrix	O
factorization	O
it	O
is	O
computationally	O
efficient	O
scaling	O
easily	O
with	O
the	O
number	O
of	O
regions	O
and	O
cancers	O
.	O

We	O
carried	O
out	O
a	O
simulation	O
study	O
to	O
evaluate	O
the	O
method	O
'	O
s	O
performance	O
and	O
apply	O
it	O
to	O
cancer	O
atlas	O
from	O
the	O
USA	O
England	O
France	O
Australia	O
Spain	O
and	O
Brazil	O
.	O

We	O
conclude	O
that	O
with	O
very	O
few	O
latent	O
maps	O
which	O
can	O
represent	O
a	O
reduction	O
of	O
up	O
to	O
90	O
of	O
atlas	O
maps	O
most	O
of	O
the	O
spatial	O
variability	O
is	O
conserved	O
.	O

By	O
concentrating	O
on	O
the	O
epidemiological	O
analysis	O
of	O
these	O
few	O
latent	O
maps	O
a	O
substantial	O
amount	O
of	O
work	O
is	O
saved	O
and	O
at	O
the	O
same	O
time	O
high	O
level	O
explanations	O
affecting	O
many	O
cancers	O
simultaneously	O
can	O
be	O
reached	O
.	O

Nonparametric	O
Biomarker	O
Based	O
Treatment	O
Selection	O
With	O
Reproducibility	O
Data	O
.	O

We	O
consider	O
evaluating	O
biomarkers	O
for	O
treatment	O
selection	O
under	O
assay	O
modification	O
.	O

Survival	O
outcome	O
treatment	O
and	O
Affymetrix	O
gene	O
expression	O
data	O
were	O
attained	O
from	O
cancer	O
patients	O
.	O

Consider	O
migrating	O
a	O
gene	O
expression	O
biomarker	O
to	O
the	O
Illumina	O
platform	O
.	O

A	O
recent	O
novel	O
approach	O
allows	O
a	O
quick	O
evaluation	O
of	O
the	O
migrated	O
biomarker	O
with	O
only	O
a	O
reproducibility	O
study	O
needed	O
to	O
compare	O
the	O
two	O
platforms	O
achieved	O
by	O
treating	O
the	O
original	O
biomarker	O
as	O
an	O
error	O
contaminated	O
observation	O
of	O
the	O
migrated	O
biomarker	O
.	O

However	O
its	O
assumptions	O
of	O
a	O
classical	O
measurement	O
error	O
model	O
and	O
a	O
linear	O
predictor	O
for	O
the	O
outcome	O
may	O
not	O
hold	O
.	O

Ignoring	O
such	O
model	O
deviations	O
may	O
lead	O
to	O
sub	O
optimal	O
treatment	O
selection	O
or	O
failure	O
to	O
identify	O
effective	O
biomarkers	O
.	O

To	O
overcome	O
such	O
limitations	O
we	O
adopt	O
a	O
nonparametric	O
logistic	O
regression	O
to	O
model	O
the	O
relationship	O
between	O
the	O
event	O
rate	O
and	O
the	O
biomarker	O
and	O
the	O
deduced	O
marker	O
based	O
treatment	O
selection	O
is	O
optimal	O
.	O

We	O
further	O
assume	O
a	O
nonparametric	O
relationship	O
between	O
the	O
migrated	O
and	O
original	O
biomarkers	O
and	O
show	O
that	O
the	O
error	O
contaminated	O
biomarker	O
leads	O
to	O
sub	O
optimal	O
treatment	O
selection	O
compared	O
to	O
the	O
error	O
free	O
biomarker	O
.	O

We	O
obtain	O
the	O
estimation	O
via	O
B	O
spline	O
approximation	O
.	O

The	O
approach	O
is	O
assessed	O
by	O
simulation	O
studies	O
and	O
demonstrated	O
through	O
application	O
to	O
lung	O
cancer	O
data	O
.	O

The	O
role	O
of	O
polypeptides	O
encoded	O
by	O
ncRNAs	O
in	O
cancer	O
.	O

It	O
was	O
previously	O
thought	O
that	O
ncRNA	O
could	O
not	O
encode	O
polypeptides	O
but	O
recent	O
reports	O
have	O
challenged	O
this	O
notion	O
.	O

As	O
research	O
into	O
ncRNA	O
progresses	O
it	O
is	O
increasingly	O
clear	O
that	O
it	O
serves	O
roles	O
beyond	O
traditional	O
mechanisms	O
playing	O
significant	O
regulatory	O
roles	O
in	O
various	O
diseases	O
notably	O
cancer	O
which	O
is	O
responsible	O
for	O
70	O
of	O
human	O
deaths	O
.	O

Numerous	O
studies	O
have	O
highlighted	O
the	O
diverse	O
regulatory	O
mechanisms	O
of	O
ncRNA	O
that	O
are	O
pivotal	O
in	O
cancer	O
initiation	O
and	O
progression	O
.	O

The	O
role	O
of	O
ncRNA	O
encoded	O
polypeptides	O
in	O
cancer	O
regulation	O
has	O
gained	O
prominence	O
.	O

This	O
article	O
explores	O
the	O
newly	O
identified	O
regulatory	O
functions	O
of	O
these	O
polypeptides	O
in	O
three	O
types	O
of	O
ncRNA	O
lncRNA	O
pri	O
miRNA	O
and	O
circRNA	O
.	O

These	O
polypeptides	O
can	O
interact	O
with	O
proteins	O
influence	O
signaling	O
pathways	O
enhance	O
miRNA	O
stability	O
and	O
regulate	O
cancer	O
progression	O
malignancy	O
resistance	O
and	O
other	O
clinical	O
challenges	O
.	O

Furthermore	O
we	O
discuss	O
the	O
evolutionary	O
significance	O
of	O
these	O
polypeptides	O
in	O
the	O
transition	O
from	O
RNA	O
to	O
protein	O
examining	O
their	O
emergence	O
and	O
conservation	O
throughout	O
evolution	O
.	O

Identifying	O
and	O
validating	O
angiogenesis	O
related	O
genes	O
remodeling	O
tumor	O
microenvironment	O
and	O
suppressing	O
immunotherapy	O
response	O
in	O
gastric	O
cancer	O
.	O

Angiogenesis	O
significantly	O
correlates	O
with	O
tumor	O
microenvironment	O
remodeling	O
and	O
immunotherapy	O
response	O
.	O

Our	O
study	O
aimed	O
to	O
construct	O
a	O
prognostic	O
angiogenesis	O
related	O
model	O
for	O
gastric	O
cancer	O
.	O

Using	O
public	O
database	O
a	O
angiogenetic	O
related	O
five	O
gene	O
FGF1	O
GRB14	O
PAK3	O
PDGFRA	O
and	O
PRKD1	O
model	O
was	O
identified	O
.	O

The	O
top	O
25	O
of	O
patients	O
were	O
defined	O
as	O
high	O
risk	O
and	O
the	O
remaining	O
as	O
low	O
risk	O
.	O

The	O
area	O
under	O
the	O
curve	O
for	O
1	O
3	O
and	O
5	O
year	O
overall	O
survival	O
OS	O
were	O
0	O
.	O
646	O
0	O
.	O
711	O
and	O
0	O
.	O
793	O
respectively	O
.	O

Survival	O
analysis	O
showed	O
a	O
better	O
10	O
year	O
OS	O
in	O
low	O
risk	O
patients	O
in	O
the	O
construction	O
HR	O
0	O
.	O
57	O
p	O
0	O
.	O
002	O
and	O
validation	O
cohorts	O
.	O

GO	O
and	O
GSEA	O
revealed	O
that	O
DEGs	O
were	O
enriched	O
in	O
extracellular	O
matrix	O
receptor	O
interactions	O
dendritic	O
cell	O
antigen	O
processing	O
presentation	O
regulation	O
and	O
angiogenesis	O
pathways	O
.	O

CIBERSORT	O
analysis	O
revealed	O
abundant	O
naive	O
B	O
cells	O
resting	O
mast	O
cells	O
resting	O
CD4	O
memory	O
T	O
cells	O
M2	O
macrophages	O
and	O
monocytes	O
in	O
high	O
risk	O
subgroups	O
.	O

The	O
TIMER	O
database	O
showed	O
strong	O
positive	O
correlations	O
between	O
PAK3	O
FGF1	O
PRKD1	O
and	O
PDGFRA	O
expression	O
levels	O
and	O
the	O
infiltration	O
of	O
CD4	O
T	O
cells	O
and	O
macrophages	O
.	O

The	O
IOBR	O
analysis	O
revealed	O
an	O
immunosuppressive	O
environment	O
in	O
the	O
high	O
risk	O
subgroup	O
.	O

Low	O
risk	O
patients	O
show	O
a	O
higher	O
response	O
rate	O
to	O
anti	O
PD1	O
treatment	O
.	O

TMA	O
showed	O
that	O
FGF1	O
overexpression	O
was	O
associated	O
with	O
poor	O
prognosis	O
and	O
CD4	O
T	O
cells	O
and	O
macrophage	O
infiltration	O
.	O

In	O
vivo	O
study	O
based	O
on	O
the	O
615	O
mice	O
indicated	O
that	O
inhibiting	O
FGF1	O
function	O
could	O
suppress	O
tumor	O
growth	O
and	O
enhance	O
anti	O
PD1	O
therapeutic	O
efficacy	O
.	O

In	O
summary	O
we	O
established	O
a	O
five	O
angiogenesis	O
related	O
gene	O
model	O
to	O
predict	O
survival	O
outcomes	O
and	O
immunotherapy	O
responses	O
in	O
patients	O
with	O
gastric	O
cancer	O
and	O
identified	O
FGF1	O
as	O
a	O
prognostic	O
gene	O
and	O
potential	O
target	O
for	O
improving	O
immune	O
treatment	O
.	O

Prostate	O
cancer	O
and	O
the	O
cell	O
cycle	O
:	O
Focusing	O
on	O
the	O
role	O
of	O
microRNAs	O
.	O

Prostate	O
cancer	O
is	O
the	O
most	O
frequent	O
solid	O
tumor	O
in	O
terms	O
of	O
incidence	O
and	O
ranks	O
second	O
only	O
to	O
lung	O
cancer	O
in	O
terms	O
of	O
cancer	O
mortality	O
among	O
men	O
.	O

It	O
has	O
a	O
considerably	O
high	O
mortality	O
rate	O
around	O
375	O
000	O
deaths	O
occurred	O
worldwide	O
in	O
2020	O
.	O

In	O
2024	O
the	O
American	O
Cancer	O
Society	O
estimated	O
that	O
the	O
number	O
of	O
new	O
prostate	O
cancer	O
cases	O
will	O
be	O
around	O
299	O
010	O
cases	O
and	O
the	O
estimated	O
deaths	O
will	O
be	O
around	O
32	O
250	O
deaths	O
only	O
in	O
the	O
USA	O
.	O

Cell	O
cycle	O
dysregulation	O
is	O
inevitable	O
in	O
cancer	O
etiology	O
and	O
is	O
targeted	O
by	O
various	O
therapies	O
in	O
cancer	O
treatment	O
.	O

MicroRNAs	O
miRNAs	O
are	O
small	O
endogenous	O
non	O
coding	O
regulatory	O
molecules	O
involved	O
in	O
both	O
normal	O
and	O
abnormal	O
cellular	O
events	O
.	O

One	O
of	O
the	O
cellular	O
processes	O
regulated	O
by	O
miRNAs	O
is	O
the	O
cell	O
cycle	O
.	O

Although	O
there	O
are	O
some	O
exceptions	O
tumor	O
suppressor	O
miRNAs	O
could	O
potentially	O
arrest	O
the	O
cell	O
cycle	O
by	O
downregulating	O
several	O
molecular	O
machineries	O
involved	O
in	O
catalyzing	O
the	O
cell	O
cycle	O
progression	O
.	O

In	O
contrast	O
oncogenic	O
miRNAs	O
oncomirs	O
help	O
the	O
cell	O
cycle	O
to	O
progress	O
by	O
targeting	O
various	O
regulatory	O
proteins	O
such	O
as	O
retinoblastoma	O
Rb	O
or	O
cell	O
cycle	O
inhibitors	O
such	O
as	O
p21	O
or	O
p27	O
and	O
hence	O
may	O
contribute	O
to	O
prostate	O
cancer	O
progression	O
however	O
this	O
is	O
not	O
always	O
the	O
case	O
.	O

In	O
this	O
review	O
we	O
emphasize	O
how	O
a	O
dysregulated	O
miRNA	O
expression	O
profile	O
is	O
linked	O
to	O
an	O
abnormal	O
cell	O
cycle	O
progression	O
in	O
prostate	O
cancer	O
which	O
subsequently	O
paves	O
the	O
way	O
to	O
a	O
new	O
therapeutic	O
option	O
for	O
prostate	O
cancer	O
.	O

Assessing	O
the	O
efficacy	O
of	O
an	O
innovative	O
diagnostic	O
method	O
for	O
identifying	O
5	O
variants	O
in	O
somatic	O
ctDNA	O
.	O

BACKGROUND	O
:	O
Liquid	O
biopsy	O
is	O
considered	O
a	O
complementary	O
and	O
recently	O
also	O
an	O
alternative	O
method	O
to	O
surgical	O
biopsy	O
.	O

It	O
allows	O
for	O
the	O
acquisition	O
of	O
valuable	O
information	O
regarding	O
the	O
potential	O
presence	O
of	O
tumors	O
particularly	O
through	O
the	O
analysis	O
of	O
circulating	O
tumor	O
DNA	O
ctDNA	O
.	O

CtDNA	O
is	O
a	O
fraction	O
of	O
circulating	O
free	O
DNA	O
cfDNA	O
that	O
can	O
be	O
extracted	O
from	O
various	O
tissues	O
with	O
blood	O
being	O
the	O
most	O
readily	O
available	O
.	O

RESULTS	O
:	O
To	O
maximize	O
the	O
yield	O
of	O
plasma	O
separation	O
specific	O
Streck	O
tubes	O
are	O
recommended	O
for	O
blood	O
collection	O
.	O

The	O
MagPurix	O
CFC	O
DNA	O
Extraction	O
Kit	O
can	O
be	O
used	O
for	O
cfDNA	O
extraction	O
and	O
the	O
TWIST	O
Library	O
Preparation	O
protocol	O
can	O
be	O
optimized	O
for	O
further	O
analysis	O
.	O

Next	O
generation	O
sequencing	O
NGS	O
can	O
be	O
employed	O
to	O
compare	O
somatic	O
and	O
germline	O
lineages	O
enabling	O
the	O
identification	O
of	O
somatic	O
variants	O
with	O
a	O
Variant	O
Allele	O
Frequency	O
VAF	O
of	O
5	O
or	O
higher	O
which	O
are	O
absent	O
in	O
the	O
germline	O
lineage	O
.	O

CONCLUSION	O
:	O
This	O
analysis	O
helps	O
in	O
the	O
assessment	O
of	O
recurrence	O
analysis	O
and	O
monitoring	O
of	O
cancer	O
tissue	O
.	O

Association	O
between	O
Toll	O
like	O
receptor	O
2	O
rs4696483	O
and	O
rs1898830	O
polymorphisms	O
and	O
the	O
risk	O
of	O
triple	O
negative	O
breast	O
cancer	O
.	O

PURPOSE	O
:	O
Breast	O
cancer	O
BC	O
is	O
heterogeneous	O
in	O
clinical	O
manifestation	O
of	O
which	O
the	O
triple	O
negative	O
TNBC	O
subtype	O
is	O
the	O
most	O
aggressive	O
.	O

This	O
study	O
examines	O
the	O
associations	O
between	O
Toll	O
Like	O
Receptor	O
TLR	O
2	O
polymorphisms	O
and	O
the	O
susceptibility	O
to	O
BC	O
and	O
TNBC	O
.	O

METHODS	O
:	O
Genotyping	O
of	O
TLR	O
2	O
rs1898830	O
and	O
rs4696483	O
polymorphisms	O
was	O
done	O
by	O
real	O
time	O
PCR	O
in	O
488	O
women	O
with	O
BC	O
130	O
TNBC	O
358	O
non	O
TNBC	O
and	O
476	O
cancer	O
free	O
control	O
women	O
.	O

RESULTS	O
:	O
The	O
minor	O
allele	O
frequency	O
MAF	O
of	O
rs4696483	O
was	O
significantly	O
lower	O
in	O
BC	O
cases	O
compared	O
to	O
controls	O
and	O
significantly	O
lower	O
frequencies	O
of	O
rs4696483	O
C	O
T	O
and	O
higher	O
frequencies	O
of	O
rs1898830	O
G	O
G	O
genotypes	O
were	O
seen	O
in	O
BC	O
cases	O
.	O

Significantly	O
higher	O
MAF	O
of	O
rs4696483	O
and	O
higher	O
C	O
T	O
and	O
T	O
T	O
rs4696483	O
genotypes	O
frequencies	O
were	O
seen	O
in	O
TNBC	O
than	O
in	O
non	O
TNBC	O
cases	O
.	O

Considering	O
the	O
prevalent	O
AC	O
haplotype	O
as	O
a	O
reference	O
2	O
locus	O
TLR	O
2	O
haplotype	O
analysis	O
did	O
not	O
identify	O
any	O
2	O
locus	O
TLR	O
2	O
haplotype	O
associated	O
with	O
an	O
altered	O
risk	O
of	O
BC	O
or	O
TNBC	O
.	O

Positive	O
associations	O
of	O
rs1898830	O
and	O
rs4966483	O
were	O
seen	O
with	O
the	O
histological	O
type	O
in	O
TNBC	O
and	O
negatively	O
with	O
distant	O
metastasis	O
and	O
HR	O
status	O
in	O
TNBC	O
and	O
non	O
TNBC	O
rs1898830	O
carriers	O
.	O

In	O
addition	O
rs4696483	O
was	O
positively	O
correlated	O
with	O
hormonotherapy	O
and	O
surgery	O
in	O
non	O
TNBC	O
cases	O
while	O
rs1898830	O
was	O
negatively	O
associated	O
with	O
hormonotherapy	O
.	O

Furthermore	O
rs1898830	O
was	O
negatively	O
and	O
positively	O
correlated	O
with	O
BMI	O
in	O
TNBC	O
and	O
TNBC	O
cases	O
respectively	O
but	O
positively	O
with	O
Ki	O
67	O
status	O
.	O

CONCLUSIONS	O
:	O
Our	O
study	O
highlights	O
the	O
association	O
between	O
TLR	O
2	O
genetic	O
polymorphisms	O
and	O
BC	O
and	O
TNBC	O
susceptibility	O
suggesting	O
these	O
variants	O
'	O
diagnostic	O
prognostic	O
capacity	O
in	O
BC	O
patients	O
and	O
patient	O
subgroups	O
.	O

Pan	O
cancer	O
analysis	O
and	O
experimental	O
validation	O
reveal	O
FAM72D	O
as	O
a	O
potential	O
novel	O
biomarker	O
and	O
therapeutic	O
target	O
in	O
lung	O
adenocarcinoma	O
.	O

BACKGROUND	O
:	O
Cancers	O
particularly	O
lung	O
adenocarcinoma	O
LUAD	O
represent	O
a	O
major	O
global	O
health	O
concern	O
.	O

However	O
the	O
role	O
of	O
FAM72D	O
in	O
various	O
cancers	O
including	O
LUAD	O
remains	O
poorly	O
understood	O
.	O

METHODS	O
:	O
We	O
utilized	O
databases	O
such	O
as	O
The	O
Cancer	O
Genome	O
Atlas	O
TCGA	O
Genotype	O
Tissue	O
Expression	O
Project	O
GTEx	O
and	O
online	O
tools	O
to	O
investigate	O
the	O
correlation	O
between	O
FAM72D	O
expression	O
and	O
its	O
prognostic	O
diagnostic	O
and	O
mutational	O
significance	O
as	O
well	O
as	O
its	O
impact	O
on	O
immune	O
cell	O
infiltration	O
across	O
multiple	O
cancers	O
.	O

Additionally	O
we	O
developed	O
LUAD	O
cell	O
lines	O
overexpressing	O
FAM72D	O
to	O
confirm	O
its	O
oncogenic	O
role	O
.	O

RESULTS	O
:	O
FAM72D	O
expression	O
was	O
elevated	O
in	O
cancerous	O
tissues	O
compared	O
to	O
noncancerous	O
tissues	O
with	O
diagnostic	O
and	O
prognostic	O
implications	O
in	O
many	O
cancers	O
including	O
LUAD	O
.	O

Moreover	O
associations	O
were	O
identified	O
between	O
FAM72D	O
expression	O
and	O
diverse	O
immune	O
subtypes	O
alongside	O
factors	O
such	O
as	O
microsatellite	O
instability	O
neoantigens	O
and	O
tumour	O
mutational	O
burden	O
across	O
pan	O
cancers	O
.	O

Additionally	O
FAM72D	O
was	O
associated	O
with	O
immune	O
infiltration	O
and	O
various	O
immune	O
checkpoint	O
related	O
genes	O
in	O
LUAD	O
.	O

In	O
vitro	O
experiments	O
demonstrated	O
that	O
FAM72D	O
promoted	O
cell	O
proliferation	O
colony	O
formation	O
and	O
migration	O
while	O
inhibiting	O
apoptosis	O
in	O
LUAD	O
cells	O
.	O

CONCLUSIONS	O
:	O
Our	O
study	O
establishes	O
associations	O
between	O
FAM72D	O
expression	O
and	O
diagnosis	O
prognosis	O
and	O
tumour	O
immunity	O
across	O
multiple	O
cancers	O
as	O
well	O
as	O
its	O
oncogenic	O
effects	O
in	O
LUAD	O
.	O

FAM72D	O
shows	O
promise	O
as	O
a	O
biomarker	O
and	O
therapeutic	O
target	O
in	O
LUAD	O
.	O

Integrin	O
alpha9	O
overexpression	O
underlies	O
the	O
niche	O
independent	O
maintenance	O
of	O
leukemia	O
stem	O
cells	O
in	O
acute	O
myeloid	O
leukemia	O
.	O

Leukemia	O
stem	O
cells	O
LSCs	O
are	O
widely	O
believed	O
to	O
reside	O
in	O
well	O
characterized	O
bone	O
marrow	O
BM	O
niches	O
however	O
the	O
capacity	O
of	O
the	O
BM	O
niches	O
to	O
accommodate	O
LSCs	O
is	O
insufficient	O
and	O
a	O
significant	O
proportion	O
of	O
LSCs	O
are	O
instead	O
maintained	O
in	O
regions	O
outside	O
the	O
BM	O
.	O

The	O
molecular	O
basis	O
for	O
this	O
niche	O
independent	O
behavior	O
of	O
LSCs	O
remains	O
elusive	O
.	O

Here	O
we	O
show	O
that	O
integrin	O
alpha9	O
overexpression	O
ITGA9	O
OE	O
plays	O
a	O
pivotal	O
role	O
in	O
the	O
extramedullary	O
maintenance	O
of	O
LSCs	O
by	O
molecularly	O
mimicking	O
the	O
niche	O
interacting	O
status	O
through	O
the	O
binding	O
with	O
its	O
soluble	O
ligand	O
osteopontin	O
OPN	O
.	O

Retroviral	O
insertional	O
mutagenesis	O
conducted	O
on	O
leukemia	O
prone	O
Runx	O
deficient	O
mice	O
identified	O
Itga9	O
OE	O
as	O
a	O
novel	O
leukemogenic	O
event	O
.	O

Itga9	O
OE	O
activates	O
Akt	O
and	O
p38MAPK	O
signaling	O
pathways	O
.	O

The	O
elevated	O
Myc	O
expression	O
subsequently	O
enhances	O
ribosomal	O
biogenesis	O
to	O
overcome	O
the	O
cell	O
integrity	O
defect	O
caused	O
by	O
the	O
preexisting	O
Runx	O
alteration	O
.	O

The	O
Itga9	O
Myc	O
axis	O
originally	O
discovered	O
in	O
mice	O
was	O
further	O
confirmed	O
in	O
multiple	O
human	O
acute	O
myeloid	O
leukemia	O
AML	O
subtypes	O
other	O
than	O
RUNX	O
leukemias	O
.	O

In	O
addition	O
ITGA9	O
was	O
shown	O
to	O
be	O
a	O
functional	O
LSC	O
marker	O
of	O
the	O
best	O
prognostic	O
value	O
among	O
14	O
known	O
LSC	O
markers	O
tested	O
.	O

Notably	O
the	O
binding	O
of	O
ITGA9	O
with	O
soluble	O
OPN	O
a	O
known	O
negative	O
regulator	O
against	O
HSC	O
activation	O
induced	O
LSC	O
dormancy	O
while	O
the	O
disruption	O
of	O
ITGA9	O
soluble	O
OPN	O
interaction	O
caused	O
rapid	O
cell	O
propagation	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
ITGA9	O
OE	O
increases	O
both	O
actively	O
proliferating	O
leukemia	O
cells	O
and	O
dormant	O
LSCs	O
in	O
a	O
well	O
balanced	O
manner	O
thereby	O
maintaining	O
LSCs	O
.	O

The	O
ITGA9	O
OE	O
would	O
serve	O
as	O
a	O
novel	O
therapeutic	O
target	O
in	O
AML	O
.	O

HNF1a	O
promotes	O
colorectal	O
cancer	O
progression	O
via	O
HKDC1	O
mediated	O
activation	O
of	O
AKT	O
AMPK	O
signaling	O
pathway	O
.	O

The	O
hepatocyte	O
nuclear	O
factor	O
1	O
HNF1a	O
is	O
a	O
transcription	O
factor	O
that	O
contributes	O
to	O
several	O
kinds	O
of	O
cancer	O
progression	O
.	O

However	O
very	O
little	O
is	O
known	O
regarding	O
the	O
mechanisms	O
underlying	O
the	O
activity	O
of	O
HNF1a	O
.	O

We	O
aimed	O
to	O
explore	O
the	O
role	O
of	O
HNF1a	O
in	O
the	O
progress	O
of	O
colorectal	O
cancer	O
CRC	O
and	O
elucidate	O
its	O
molecular	O
mechanism	O
.	O

HNF1a	O
expression	O
was	O
upregulated	O
in	O
CRC	O
samples	O
and	O
high	O
expression	O
of	O
HNF1a	O
was	O
associated	O
with	O
poor	O
prognosis	O
of	O
CRC	O
patients	O
.	O

HNF1alpha	O
knockdown	O
and	O
overexpression	O
inhibited	O
and	O
promoted	O
proliferation	O
migration	O
and	O
invasion	O
of	O
CRC	O
cells	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
respectively	O
.	O

Mechanistically	O
HNF1a	O
increased	O
the	O
transcriptional	O
activity	O
of	O
hexokinase	O
domain	O
component	O
1	O
HKDC1	O
promoter	O
thus	O
activated	O
AKT	O
AMPK	O
signaling	O
.	O

Meanwhile	O
HKDC1	O
upregulation	O
was	O
important	O
for	O
the	O
proliferation	O
migration	O
and	O
invasion	O
of	O
CRC	O
cells	O
and	O
knockdown	O
of	O
HKDC1	O
significantly	O
reversed	O
the	O
proliferation	O
migration	O
and	O
invasion	O
induced	O
by	O
HNF1alpha	O
overexpression	O
.	O

Taken	O
together	O
HNF1a	O
contributes	O
to	O
CRC	O
progression	O
and	O
metastasis	O
through	O
binding	O
to	O
HKDC1	O
and	O
activating	O
AKT	O
AMPK	O
signaling	O
.	O

Targeting	O
HNF1a	O
could	O
be	O
a	O
potential	O
therapeutic	O
strategy	O
for	O
CRC	O
patients	O
.	O


